Pitcairn’s Ionis Pharmaceuticals IONS Stock Holding History

Pitcairn’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,075	Closed	-$267K	–	275
2025 Q3	$267K	Buy	+4,075	New	+$199K	0.02%	533

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Pitcairn's IONS Position: Q4 2025 in Review

Pitcairn sold out of Ionis Pharmaceuticals (IONS) in Q4 2025, closing a stake of 4,075 shares — an estimated $267K sold.

Pitcairn first reported a position in IONS in Q3 2025 and held it in 1 quarter. The position peaked at $267K in Q3 2025. 491 funds tracked by Wall St. Rank hold IONS as of Q4 2025.

Pitcairn reported no remaining Ionis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Pitcairn sold 4,075 Ionis Pharmaceuticals shares in Q4 2025, an estimated $267K.
Pitcairn first reported a position in Ionis Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Pitcairn's Ionis Pharmaceuticals position peaked at $267K in Q3 2025.
491 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2025.

Based on Pitcairn's 13F filing for Q4 2025.